Sign in to view content

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO

Nikhil K Bommakanti, MD

Video
Published 2024

Related

Fluctuations in Central Subfield Thickness Associated With Worse Visual Outcomes in Patients With Diabetic Macular Edema in Clinical Trial Setting
Matthew Starr, MD
Annual Meeting Talks
2021
Multiwavelength Photobiomodulation Significantly Reduces Risk for Vision Loss and Onset of Geographic Atrophy in Dry Age-Related Macular Degeneration
Eleonora Lad, MD, PhD
Updates from the Field
2024
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019

Category: AMD-Neovascular

See more